Farmacogenômica e transtornos afetivos: origens, fundamentos e aplicabilidade clínica
DOI:
https://doi.org/10.25118/2763-9037.2012.v2.889Palavras-chave:
transtornos afetivos, farmacogenética, farmacogenômica, antidepressivosResumo
A possibilidade de um tratamento personalizado (a adaptação das terapias com base no perfil genético de cada paciente) é um dos aspectos promissores da farmacoterapia dos transtornos afetivos. A identificação da relação entre genótipo e resposta a antidepressivos, incluindo tanto o efeito terapêutico como o perfil de efeitos adversos, pode vir a alterar profundamente a prática médica. No presente artigo de atualização, procuramos rever os fundamentos desse campo de pesquisa chamado de farmacogenética ou farmacogenômica aplicado aos transtornos afetivos, partindo dos fundamentos genéticos dos transtornos afetivos, passando pelo conhecimento atual a respeito dos genes associados à resposta a antidepressivos, e sinalizando possíveis razões para os achados ainda inconsistentes dos estudos nesse campo.
Downloads
Métricas
Referências
Trivedi MH, Rush a J, Wisniewski SR, Nierenberg A a, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. The American journal of Psychiatry,.2006;163:28–40. DOI: https://doi.org/10.1176/appi.ajp.163.1.28
Malhotra A, Murphy G. Pharmacogenetics of psychotropic drug response. The American Journal of Psychiatry, 2004;161:780–96. DOI: https://doi.org/10.1176/appi.ajp.161.5.780
Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research, 1998;32:255–9. DOI: https://doi.org/10.1016/S0022-3956(98)00004-1
O’Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry, 1994;36:467–71. DOI: https://doi.org/10.1016/0006-3223(94)90642-4
Mcguffin P. Genetic Research in Psychiatry. In: Psychiatry as a Neuroscience. 2002. p. 1–27. DOI: https://doi.org/10.1002/0470846461.ch1
Galton F. Hereditary genius. London: McMillan, 1892.
McGuffin P. Genomics and behavior: Toward Behavioral Genomics. Science, 2001;291:1232–49. DOI: https://doi.org/10.1126/science.1057264
Van Praag H. Mood and Anxiety Disorders. A diagnostic pleonasm. In: Nutt D, Ballenger JC, editores. Anxiety Disorders. Oxford: Blackwell Science, 2003.
Roses a D. Pharmacogenetics and future drug development and delivery. Lancet, 2000;355:1358–61. DOI: https://doi.org/10.1016/S0140-6736(00)02126-7
Hettema JM. What is the genetic relationship between anxiety and depression? American journal of medical genetics. Part C, Seminars in Medical Genetics, 2008;148C:140–6. DOI: https://doi.org/10.1002/ajmg.c.30171
Huezo-Diaz P, Tandon K, Aitchison KJ. The genetics of depression and related traits. Current Psychiatry Reports, 2005;7:117–24. DOI: https://doi.org/10.1007/s11920-005-0008-5
Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet, 2011;379:1045–55. DOI: https://doi.org/10.1016/S0140-6736(11)60602-8
Mrazek D. Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010. DOI: https://doi.org/10.1093/med/9780195367294.001.0001
Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica, 2001;104:173–92. DOI: https://doi.org/10.1034/j.1600-0447.2001.00299.x
Weinshilboum R. Inheritance and drug response. The New England journal of medicine, 2003;348:529–37. DOI: https://doi.org/10.1056/NEJMra020021
Berg A, Piper M, Armstrong K, Botkin J, Haddow J. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007;9:819–25. DOI: https://doi.org/10.1097/GIM.0b013e31815bf9a3
Lesch KP, Bengel D, Heils a, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 1996;274:1527–31. DOI: https://doi.org/10.1126/science.274.5292.1527
Serretti a, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular psychiatry, 2007;12:247–57. DOI: https://doi.org/10.1038/sj.mp.4001926
Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular psychiatry, 2010;15:473–500. DOI: https://doi.org/10.1038/mp.2008.116
Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. Journal of psychiatry & neuroscience , 2011;36: 87–113. DOI: https://doi.org/10.1503/jpn.100059
Suarez-kurtz G. Pharmacogenomics in Admixed Populations. Austin: Landes Bioscience, 2007. DOI: https://doi.org/10.1201/9781498713795
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2012 Vitor de Mello Netto
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
